Estrogen

University of Phoenix Recognized With 2023 Academia Circle of Excellence Award by EC-Council, World’s Largest Cybersecurity Certification Body

Retrieved on: 
Thursday, February 29, 2024

University of Phoenix is proud to share it is a recipient of the EC-Council 2023 Academia Circle of Excellence Award for the fifth consecutive year.

Key Points: 
  • University of Phoenix is proud to share it is a recipient of the EC-Council 2023 Academia Circle of Excellence Award for the fifth consecutive year.
  • “We are incredibly proud to receive the EC-Council Academia Circle of Excellence Award for the fifth year in a row,” states Kathryn Uhles, dean, College of Business and Information Technology at the University.
  • “We are extremely proud to award University of Phoenix the Circle of Excellence awards based on their commitment to Cybersecurity education at large.
  • The award recognizes the University’s commitment to making a positive impact in the cybersecurity workforce.

Ribometrix Demonstrates Rapid Progress for eIF4E Program at San Antonio Breast Cancer Symposium

Retrieved on: 
Friday, December 8, 2023

Ribometrix , a biotechnology company developing small molecule therapeutics that modulate RNA biology, today presented preclinical data supporting the potential of its eIF4E inhibitors in Estrogen Receptor-positive (ER+) breast cancer at the annual San Antonio Breast Cancer Symposium (SABCS), held December 5-9, 2023, in San Antonio, TX.

Key Points: 
  • Ribometrix , a biotechnology company developing small molecule therapeutics that modulate RNA biology, today presented preclinical data supporting the potential of its eIF4E inhibitors in Estrogen Receptor-positive (ER+) breast cancer at the annual San Antonio Breast Cancer Symposium (SABCS), held December 5-9, 2023, in San Antonio, TX.
  • Ribometrix’s preclinical studies in ER+ breast cancer include evaluation of eIF4E inhibition via both monotherapy and in combination with standard-of-care (SoC) CDK4/6 inhibitors, which target key pro-oncogenic signaling pathways shared with eIF4E.
  • Furthermore, eIF4E controls parts of the pathway that complement those targeted by CDK4/6 inhibition, suggesting additive benefit from combined therapy.
  • “We are encouraged to see the added validation of eIF4E as an important mediator of pro-oncogenic signaling, this time in ER+ breast cancer, and the excellent emerging profiles of our eIF4E inhibitors.

Ribometrix to Present Additional Preclinical Data for eIF4E Program at the San Antonio Breast Cancer Symposium

Retrieved on: 
Wednesday, November 29, 2023

Ribometrix , a biotechnology company developing small molecule therapeutics that modulate RNA biology, today announced it will present preclinical data showing anti-tumor benefit of eIF4E inhibition in Estrogen Receptor-positive (ER+) breast cancer at the annual San Antonio Breast Cancer Symposium, held December 5-9, 2023, in San Antonio, TX.

Key Points: 
  • Ribometrix , a biotechnology company developing small molecule therapeutics that modulate RNA biology, today announced it will present preclinical data showing anti-tumor benefit of eIF4E inhibition in Estrogen Receptor-positive (ER+) breast cancer at the annual San Antonio Breast Cancer Symposium, held December 5-9, 2023, in San Antonio, TX.
  • Ribometrix is evaluating its portfolio of inhibitors targeting eIF4E in preclinical studies in cancer, including melanoma and breast cancer.
  • eIF4E is both a potent oncogene and a regulator of resistance to therapies targeting common oncogenic drivers, and Ribometrix’s data support the potential efficacy of its eIF4E inhibitors alone or in combination with standard-of-care in treatment naïve and treatment-resistant settings.
  • At the time of presentation, Ribometrix’s poster will be made available on the “Publications” page of the “News” section of its website.

Sermonix Pharmaceuticals Announces JCO Precision Oncology Publication of Case Report on a Complete Remission in a Metastatic Breast Cancer Patient Participating in ELAINE-1 Trial

Retrieved on: 
Monday, November 6, 2023

The open-access case report, “ Lasofoxifene Monotherapy Induces Durable Complete Remission in a Patient with ER+, HER2- Metastatic Breast Cancer with an ESR1 Mutation ,” details a patient result that was reported during Sermonix’s Evaluation of Lasofoxifene in ESR1 Mutations (ELAINE-1, NCT03781063) study.

Key Points: 
  • The open-access case report, “ Lasofoxifene Monotherapy Induces Durable Complete Remission in a Patient with ER+, HER2- Metastatic Breast Cancer with an ESR1 Mutation ,” details a patient result that was reported during Sermonix’s Evaluation of Lasofoxifene in ESR1 Mutations (ELAINE-1, NCT03781063) study.
  • The case was previously presented as a poster and brief talk at the annual Metastatic Breast Cancer Research Conference in September 2022.
  • Topline results from the ELAINE-1 trial, including this patient, were reported at the European Society for Medical Oncology (ESMO) Congress 2022.
  • 5Jeselsohn R, De Angelis C, Brown M, et al: The Evolving Role of the Estrogen Receptor Mutations in Endocrine Therapy-Resistant Breast Cancer.

Besins Healthcare Unveils State-of-the-Art Hormone Factory in Muel, Spain, Amplifying Global Production Capabilities by 30%

Retrieved on: 
Wednesday, September 27, 2023

MONACO, Sept. 26, 2023 /PRNewswire/ -- Besins Healthcare, a global lead in Women's and Men's Reproductive Health, today unveiled its novel hormone production facility in Muel, situated near Zaragoza, Spain. This event represents a significant moment in European pharmaceutical history.

Key Points: 
  • MONACO, Sept. 26, 2023 /PRNewswire/ -- Besins Healthcare, a global lead in Women's and Men's Reproductive Health, today unveiled its novel hormone production facility in Muel, situated near Zaragoza, Spain.
  • Built in an astounding time frame since its foundation in mid-2022, this avant-garde facility adheres to the highest quality complying with the highest environmental standards.
  • The plant fortifies Besins Healthcare's commitment to scale up production capacities within Europe, boosting their output by an impressive 30%.
  • Following its strategic acquisition of a hormone production site in Drogenbos, Belgium, in 2022, Besins Healthcare continues to reinforce its commitment to the European Union's initiative to mitigate drug shortages and establish pharmaceutical sovereignty (1).

Mithra and Searchlight Pharma Announce Donesta® Licensing Agreement for Canada

Retrieved on: 
Monday, July 31, 2023

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230731182336/en/
    Under the binding terms, Searchlight will have the exclusive sales and marketing rights for Donesta® in Canada.
  • Searchlight will be responsible for obtaining and maintaining any regulatory approvals required to market and sell Donesta® in Canada.
  • David Horn Solomon, Chief Executive Officer of Mithra, commented: “We are very pleased to reach this agreement with Searchlight Pharma for the licensing of Donesta® in Canada.
  • Mithra and Searchlight have a continuing partnership for NEXTSTELLIS®, a combined oral contraceptive product based on Estetrol, and HALOETTE®, a vaginal contraceptive ring in Canada.

Mithra and Searchlight Pharma Announce Donesta® Licensing Agreement for Canada

Retrieved on: 
Monday, July 31, 2023

Under the binding terms, Searchlight will have the exclusive sales and marketing rights for Donesta® in Canada.

Key Points: 
  • Under the binding terms, Searchlight will have the exclusive sales and marketing rights for Donesta® in Canada.
  • Searchlight will be responsible for obtaining and maintaining any regulatory approvals required to market and sell Donesta® in Canada.
  • David Horn Solomon, Chief Executive Officer of Mithra, commented: “We are very pleased to reach this agreement with Searchlight Pharma for the licensing of Donesta® in Canada.
  • Mithra and Searchlight have a continuing partnership for NEXTSTELLIS®, a combined oral contraceptive product based on Estetrol and HALOETTE®, a vaginal contraceptive ring in Canada.

Slynd® (drospirenone) is now covered by the Régie de l’assurance maladie du Québec

Retrieved on: 
Wednesday, July 12, 2023

"Securing public reimbursement coverage is an important milestone for the whole healthcare ecosystem of Quebec, as it provides access to women of reproductive age a new branded estrogen-free contraceptive option", said Dany Hallé, Vice-president, Commercial Affairs at Duchesnay Pharmaceutical Group.

Key Points: 
  • "Securing public reimbursement coverage is an important milestone for the whole healthcare ecosystem of Quebec, as it provides access to women of reproductive age a new branded estrogen-free contraceptive option", said Dany Hallé, Vice-president, Commercial Affairs at Duchesnay Pharmaceutical Group.
  • "Slynd’s reimbursement coverage by the Régie de l’assurance maladie du Québec will play a significant role in facilitating and expanding access to this cutting-edge contraception option approved in Canada."
  • “It will be extremely useful in particular because of its extended missed-dose window as well as for a vast majority of women who can take this new option.
  • The product monograph is also available through our Medical Information Department.

Phase 2 Study of Upadacitinib (RINVOQ®) Alone or as a Combination Therapy Meets Primary and Key Secondary Endpoints in Patients with Systemic Lupus Erythematosus

Retrieved on: 
Wednesday, May 31, 2023

NORTH CHICAGO, Ill., May 31, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the results of the Phase 2 SLEek study evaluating upadacitinib (RINVOQ® 30 mg) alone and in combination [ABBV-599 high dose (elsubrutinib 60 mg and upadacitinib 30 mg)] in adults with moderately to severely active systemic lupus erythematosus (SLE) who continued to receive standard lupus therapies. The study results are being presented as an oral presentation during the European Congress of Rheumatology, EULAR 2023.

Key Points: 
  • - Upadacitinib maintained greater improvements in SLE disease activity at week 48 as measured by the British Isles Lupus Assessment Group-Based Composite Lupus Assessment (BICLA), SRI-4, Lupus Low Disease Activity State (LLDAS) and lupus flares compared with placebo2
    - No new safety signals were observed beyond the known safety profile for upadacitinib.
  • The study results are being presented as an oral presentation during the European Congress of Rheumatology, EULAR 2023.
  • "As a leader in immunology, AbbVie is committed to advancing care in areas of unmet need, such as SLE.
  • We are encouraged by these positive Phase 2 data and look forward to continuing to study upadacitinib for systemic lupus erythematosus in two Phase 3 trials as part of our ongoing clinical program."

Mithra - Letter to Shareholders and Corporate Update

Retrieved on: 
Thursday, May 25, 2023

Donesta® filing rescheduled for H2 2023 - still expecting U.S. approval in H1 2024

Key Points: 
  • Donesta® filing rescheduled for H2 2023 - still expecting U.S. approval in H1 2024
    Liege, Belgium, 25 May 2023 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, (the "Company" or "Mithra"), today published a Corporate Update and Letter to Shareholders from recently appointed Chief Executive Officer, Dr. David Horn Solomon.
  • I accepted the role because my analysis revealed strong fundamentals and tremendous potential to create significant value for Mithra shareholders.
  • Collectively, the Mithra leadership understands that our ability to create value for our shareholders is a primary directive that goes hand in hand with developing medicines for women.
  • I look forward to continuing with increased transparency and regular communications to providing updates on our progress to you, our shareholders.